Reports robust disease control with extended faricimab dosing in nAMD, suggesting potential for less frequent treatment.
Patients with nAMD in TENAYA/LUCERNE always on extended faricimab dosing (≥12-weeks) achieved robust disease control throughout 2 years. Additionally, 56% of patients could have potentially extended to every-20-week dosing had the protocol allowed.
No takes yet. Share an insight, caveat, or question.
Ambresin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: